Ray Dalio Sarepta Therapeutics, Inc. Transaction History
Bridgewater Associates, LP
- $23.8 Billion
- Q3 2025
A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 352,275 shares of SRPT stock, worth $6.63 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
352,275Holding current value
$6.63 Million% of portfolio
0.03%Shares
15 transactions
Others Institutions Holding SRPT
# of Institutions
406Shares Held
83.7MCall Options Held
5.27MPut Options Held
5.94M-
Vanguard Group Inc Valley Forge, PA10.8MShares$203 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$194 Million0.04% of portfolio
-
State Street Corp Boston, MA5.3MShares$99.8 Million0.0% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.69MShares$50.5 Million0.49% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.65MShares$49.8 Million0.07% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.65B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...